Expand New Drugs for TB [endTB]
- Conditions
- Tuberculosis, Multidrug-Resistant
- Registration Number
- NCT03259269
- Lead Sponsor
- Partners in Health
- Brief Summary
This observational study will examine the safety and efficacy of bedaquiline and delamanid used (individually, not together) in routine, multidrug regimens for treatment of MDR-TB. The information gathered in this study will inform doctors how best to use these TB drugs in the future.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2804
- Any patient who receives a treatment regimen containing bedaquiline or delamanid at an endTB site will be invited to participate in this observational study, regardless of age or gender.
- Any patient who signs the study informed consent form will be included in the study.
- Refusal to participate in the study.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method End of treatment outcome 20 - 24 months of treatment Final outcomes: cured, treatment completed, treatment failed, lost to follow-up, died, not evaluated
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (16)
National Treatment Centre for Tuberculosis, Abovian, Armenia
🇦🇲Abovyan, Armenia
National Institute of Diseases of the Chest and Hospital (NIDCH), Dhaka
🇧🇩Dhaka, Bangladesh
Republican Research and Practical Centre for Pulmonology and Tuberculosis
🇧🇾Minsk, Belarus
Bishoftu Hospital
🇪🇹Bishoftu, Ethiopia
National Center for Tuberculosis and Lung Diseases
🇬🇪Tbilisi, Georgia
RS Islam Jakarta Cempaka Putih
🇮🇩Jakarta, Indonesia
National Research Center for Phthisionpulmonology
🇰🇿Almaty, Kazakhstan
MSF Tuberculosis clinic, Mathare, Nairobi, Kenya
🇰🇪Nairobi, Kenya
Kara-Suu District TB hospital
🇰🇬Kara-Suu, Kyrgyzstan
Botshabelo Hospital
🇱🇸Maseru, Lesotho
Scroll for more (6 remaining)National Treatment Centre for Tuberculosis, Abovian, Armenia🇦🇲Abovyan, Armenia